|
US5703055A
(en)
|
1989-03-21 |
1997-12-30 |
Wisconsin Alumni Research Foundation |
Generation of antibodies through lipid mediated DNA delivery
|
|
US5545130A
(en)
|
1992-04-08 |
1996-08-13 |
Genetronics, Inc. |
Flow through electroporation method
|
|
US5702359A
(en)
|
1995-06-06 |
1997-12-30 |
Genetronics, Inc. |
Needle electrodes for mediated delivery of drugs and genes
|
|
US5679647A
(en)
|
1993-08-26 |
1997-10-21 |
The Regents Of The University Of California |
Methods and devices for immunizing a host against tumor-associated antigens through administration of naked polynucleotides which encode tumor-associated antigenic peptides
|
|
US5869326A
(en)
|
1996-09-09 |
1999-02-09 |
Genetronics, Inc. |
Electroporation employing user-configured pulsing scheme
|
|
US20020173629A1
(en)
|
1997-05-05 |
2002-11-21 |
Aya Jakobovits |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6235883B1
(en)
|
1997-05-05 |
2001-05-22 |
Abgenix, Inc. |
Human monoclonal antibodies to epidermal growth factor receptor
|
|
US6055453A
(en)
|
1997-08-01 |
2000-04-25 |
Genetronics, Inc. |
Apparatus for addressing needle array electrodes for electroporation therapy
|
|
US6216034B1
(en)
|
1997-08-01 |
2001-04-10 |
Genetronics, Inc. |
Method of programming an array of needle electrodes for electroporation therapy of tissue
|
|
US6241701B1
(en)
|
1997-08-01 |
2001-06-05 |
Genetronics, Inc. |
Apparatus for electroporation mediated delivery of drugs and genes
|
|
US6208893B1
(en)
|
1998-01-27 |
2001-03-27 |
Genetronics, Inc. |
Electroporation apparatus with connective electrode template
|
|
US6120493A
(en)
|
1998-01-27 |
2000-09-19 |
Genetronics, Inc. |
Method for the introduction of therapeutic agents utilizing an electroporation apparatus
|
|
US6302874B1
(en)
|
1998-07-13 |
2001-10-16 |
Genetronics, Inc. |
Method and apparatus for electrically assisted topical delivery of agents for cosmetic applications
|
|
US6192270B1
(en)
|
1998-08-14 |
2001-02-20 |
Genetronics, Inc. |
Apparatus and method for the delivery of drugs and genes into tissue
|
|
US6150148A
(en)
|
1998-10-21 |
2000-11-21 |
Genetronics, Inc. |
Electroporation apparatus for control of temperature during the process
|
|
US7245963B2
(en)
|
2002-03-07 |
2007-07-17 |
Advisys, Inc. |
Electrode assembly for constant-current electroporation and use
|
|
JP2005522514A
(ja)
|
2002-04-10 |
2005-07-28 |
ジェネンテック・インコーポレーテッド |
抗her2抗体改変体
|
|
ME01803B
(me)
|
2004-08-05 |
2010-12-31 |
Genentech Inc |
Humanizovani anti-cmet antagonisti
|
|
GB0503546D0
(en)
|
2005-02-21 |
2005-03-30 |
Hellenic Pasteur Inst |
Antibody
|
|
CA2628253A1
(en)
|
2005-11-03 |
2007-08-30 |
Genentech, Inc. |
Therapeutic anti-her2 antibody fusion polypeptides
|
|
UA96139C2
(uk)
|
2005-11-08 |
2011-10-10 |
Дженентек, Інк. |
Антитіло до нейропіліну-1 (nrp1)
|
|
US20100143340A1
(en)
|
2006-12-13 |
2010-06-10 |
Schering Corporation |
Methods and compositions for treating cancer
|
|
PL2155788T3
(pl)
*
|
2007-04-03 |
2013-02-28 |
Amgen Res Munich Gmbh |
Swoiste międzygatunkowe bispecyficzne czynniki wiążące
|
|
US9469691B2
(en)
|
2008-12-02 |
2016-10-18 |
Pierre Fabre Medicament |
Anti-cMET antibody
|
|
US20140112911A9
(en)
|
2008-12-02 |
2014-04-24 |
Liliane Goetsch |
Novel anti-cmet antibody
|
|
WO2010064089A1
(en)
|
2008-12-02 |
2010-06-10 |
Pierre Fabre Medicament |
Novel anti-cmet antibody
|
|
WO2010099186A1
(en)
|
2009-02-25 |
2010-09-02 |
Merck Sharp & Dohme Corp. |
Her2 antibody compositions
|
|
EP2287197A1
(en)
|
2009-08-21 |
2011-02-23 |
Pierre Fabre Medicament |
Anti-cMET antibody and its use for the detection and the diagnosis of cancer
|
|
WO2011057064A1
(en)
|
2009-11-05 |
2011-05-12 |
Brian Long |
Igf1r inhibitor based treatment of prostate cancer
|
|
CN102167742B
(zh)
|
2010-02-25 |
2014-05-14 |
上海百迈博制药有限公司 |
一种全人源抗her2单克隆抗体、其制备方法及用途
|
|
EP3904391B1
(en)
|
2010-03-10 |
2024-07-10 |
Genmab A/S |
Monoclonal antibodies against c-met
|
|
WO2011143408A1
(en)
|
2010-05-13 |
2011-11-17 |
Genentech, Inc. |
Use of neuropilin-1 antagonists for the treatment of cancer
|
|
JP5908972B2
(ja)
|
2011-04-07 |
2016-04-26 |
アムジエン・インコーポレーテツド |
新規な抗原結合タンパク質
|
|
AU2012255920A1
(en)
|
2011-05-18 |
2013-11-07 |
Merck Sharp & Dohme Corp. |
Therapeutic anti-IGF1R combinations
|
|
CN102492039B
(zh)
|
2011-11-21 |
2015-03-11 |
无锡天演生物技术有限公司 |
全人源抗人her2单抗
|
|
EP2863947B1
(en)
|
2012-06-21 |
2018-03-07 |
Sorrento Therapeutics, Inc. |
Antigen binding proteins that bind igf1r
|
|
WO2014189303A1
(ko)
|
2013-05-23 |
2014-11-27 |
아주대학교산학협력단 |
뉴로필린에 특이적인 종양 침투성 펩타이드 및 이 펩타이드가 융합된 융합 단백질
|
|
JP6541237B2
(ja)
|
2014-03-06 |
2019-07-10 |
ナショナル リサーチ カウンシル オブ カナダ |
インスリン様成長因子1受容体特異的抗体及びそれらの使用
|
|
EP3114142B1
(en)
|
2014-03-06 |
2019-06-05 |
National Research Council of Canada |
Insulin-like growth factor 1 receptor -specific antibodies and uses thereof
|
|
US9975960B2
(en)
|
2014-05-09 |
2018-05-22 |
Samsung Electronics Co., Ltd. |
Anti-HER2 antibody and anti-c-Met/anti-HER2 bispecific antibodies comprising the same
|
|
KR101551306B1
(ko)
|
2015-03-23 |
2015-09-09 |
아주대학교산학협력단 |
뉴로필린1 특이적 결합 펩타이드 및 이 펩타이드가 융합된 융합 단백질, 및 이의 용도
|
|
ES3043088T3
(en)
|
2015-06-17 |
2025-11-24 |
Hoffmann La Roche |
Anti-her2 antibodies and methods of use
|
|
WO2017171373A2
(ko)
*
|
2016-03-29 |
2017-10-05 |
아주대학교산학협력단 |
Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
|
|
KR102048474B1
(ko)
|
2016-03-29 |
2019-11-26 |
아주대학교산학협력단 |
Egfr 표적 제제에 대한 저항성을 억제하기 위한 조성물
|
|
KR101985299B1
(ko)
|
2016-06-03 |
2019-09-03 |
삼성전자주식회사 |
항-c-Met/항-Nrp1 이중 특이 항체
|
|
US10167342B2
(en)
|
2016-08-29 |
2019-01-01 |
Fazel Shokri |
Production of hersintuzumab: a new humanized antibody against HER2 for cancer treatment
|
|
LT3512882T
(lt)
|
2016-09-14 |
2021-06-25 |
Merck Patent Gmbh |
Anti-c-met antikūnai ir jų antikūno-vaisto konjugatai, skirti efektyviam naviko slopinimui
|
|
JOP20190134A1
(ar)
|
2016-12-23 |
2019-06-02 |
Potenza Therapeutics Inc |
بروتينات رابطة لمولد ضد مضادة لنيوروبيلين وطرق استخدامها
|
|
EP3615571A1
(en)
*
|
2017-04-24 |
2020-03-04 |
Ichnos Sciences SA |
T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
|
|
EP3680250A4
(en)
|
2017-09-08 |
2021-07-14 |
Ajou University Industry-Academic Cooperation Foundation |
COMPOSITION LIMITING THE ACTIVITY OF A REGULATING T LYMPHOCYTE, INCLUDING A PEPTIDIC BINDING SPECIFIC TO NEUROPILIN 1 (NRP1)
|
|
KR102054389B1
(ko)
|
2017-10-26 |
2019-12-11 |
아주대학교산학협력단 |
뉴로필린1에 특이적으로 결합하는 Non-CendR 펩타이드, 상기 펩타이드가 융합된 융합 단백질 및 이의 용도
|
|
KR102956998B1
(ko)
|
2018-07-31 |
2026-04-27 |
도꾜 다이가꾸 |
새로운 결합 특이성을 항체에 부여하는 초범용법
|
|
EP3867273A1
(en)
|
2018-10-19 |
2021-08-25 |
Ichnos Sciences SA |
T cell redirecting bispecific antibodies for the treatment of squamous cell cancers
|
|
JP2022510218A
(ja)
|
2018-11-30 |
2022-01-26 |
メモリアル スローン ケタリング キャンサー センター |
ヘテロ二量体四価特異性抗体およびこれらの使用
|
|
MX2021008121A
(es)
|
2019-01-03 |
2021-12-10 |
Inst Nat Sante Rech Med |
Metodos y composiciones farmaceuticas para mejorar las respuestas inmunitarias dependientes de celulas t cd8+ en sujetos que sufren de cancer.
|
|
WO2022026943A2
(en)
|
2020-07-31 |
2022-02-03 |
Pinetree Therapeutics, Inc. |
Neuropilin and angiotensin converting enzyme 2 fusion peptides for treating viral infections
|
|
IL315960A
(en)
|
2022-03-30 |
2024-11-01 |
Pinetree Therapeutics Inc |
Bispecific antibodies comprising an nrp1 binding domain and methods of use thereof
|
|
IL320410A
(en)
|
2022-11-07 |
2025-06-01 |
Pinetree Therapeutics Inc |
Combination therapy involving bispecific antibodies containing an NRP1 binding domain
|
|
EP4754135A1
(en)
|
2023-07-28 |
2026-06-10 |
Pinetree Therapeutics, Inc. |
Non-receptor tyrosine kinase compositions for targeted lysosomal degradation and methods of use thereof
|